INDISULAM

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H12ClN3O4S2
Molecular Weight	385.846
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NS(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)NC2=C3NC=C(Cl)C3=CC=C2

InChI

InChIKey=SETFNECMODOHTO-UHFFFAOYSA-N

InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)

HIDE SMILES / InChI

Molecular Formula	C14H12ClN3O4S2
Molecular Weight	385.846
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29660836 | https://www.ncbi.nlm.nih.gov/pubmed/18414469 | https://www.ncbi.nlm.nih.gov/pubmed/12556221 |

Indisulam (also known as E7070) is a sulfonamide derivative patented by Japanese pharmaceutical company Eisai Co. as antitumor agent. Indisulam inhibits cyclin-dependent kinases (CDK), which regulate cell cycle progression and are usually over-expressed in cancerous cells. Inhibition of CDK results in G1/S phase arrest of the cell cycle, and may lead to induction of apoptosis and inhibition of tumor cell proliferation. Preclinical and clinical studies have established the synergy of indisulam with nucleoside analogs as well as topoisomerase inhibitors. These combinations were tolerated with acceptable toxicities, including diarrhea, vomiting, and myelosuppression. In Phase II clinical trials Combination of indisulam with DNA‐damaging agent (idarubicin) and nucleoside analog (cytarabine) in patients with relapsed and refractory AML is effective and largely well tolerated.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Carbonic anhydrase I 62 Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14698154	Inhibitor 8504	31.0 nM [IC50]
Carbonic anhydrase VI 17 Target ID: CHEMBL3025 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17228881	Inhibitor 8504	47.0 nM [Ki]
Carbonic anhydrase II 88 Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14698154	Inhibitor 8504	15.0 nM [IC50]
Carbonic anhydrase IX 36 Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17228881	Inhibitor 8504	24.0 nM [Ki]

C_max

Value	Dose	Analyte	Population
1468 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	10 mg/m² single, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2044 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	13 mg/m² single, intravenous dose: 13 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3307 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	26 mg/m² single, intravenous dose: 26 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7756 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	52 mg/m² single, intravenous dose: 52 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
16324 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	104 mg/m² single, intravenous dose: 104 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20958 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	130 mg/m² single, intravenous dose: 130 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18331 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	160 mg/m² single, intravenous dose: 160 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18815 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	160 mg/m² single, intravenous dose: 160 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1296 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	10 mg/m² 1 times / day steady-state, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2228 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	13 mg/m² 1 times / day steady-state, intravenous dose: 13 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3337 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	26 mg/m² 1 times / day steady-state, intravenous dose: 26 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8125 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	52 mg/m² 1 times / day steady-state, intravenous dose: 52 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
19050 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	104 mg/m² 1 times / day steady-state, intravenous dose: 104 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
34129 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	130 mg/m² 1 times / day steady-state, intravenous dose: 130 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
34391 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	160 mg/m² 1 times / day steady-state, intravenous dose: 160 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
66835 ng/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	200 mg/m² 1 times / day steady-state, intravenous dose: 200 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
117.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16232205/	800 mg/m² 1 times / 3 weeks steady-state, intravenous dose: 800 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
3374 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	10 mg/m² single, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4585 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	13 mg/m² single, intravenous dose: 13 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7747 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	26 mg/m² single, intravenous dose: 26 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17041 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	52 mg/m² single, intravenous dose: 52 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
50518 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	104 mg/m² single, intravenous dose: 104 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
80996 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	130 mg/m² single, intravenous dose: 130 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
66453 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	160 mg/m² single, intravenous dose: 160 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
137569 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	160 mg/m² single, intravenous dose: 160 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5096 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	10 mg/m² 1 times / day steady-state, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7183 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	13 mg/m² 1 times / day steady-state, intravenous dose: 13 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10292 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	26 mg/m² 1 times / day steady-state, intravenous dose: 26 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26072 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	52 mg/m² 1 times / day steady-state, intravenous dose: 52 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
169306 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	104 mg/m² 1 times / day steady-state, intravenous dose: 104 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
470847 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	130 mg/m² 1 times / day steady-state, intravenous dose: 130 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
506676 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	160 mg/m² 1 times / day steady-state, intravenous dose: 160 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
887389 ng × h/mL EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	200 mg/m² 1 times / day steady-state, intravenous dose: 200 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3943 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16232205/	800 mg/m² 1 times / 3 weeks steady-state, intravenous dose: 800 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
25.98 h EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	10 mg/m² 1 times / day steady-state, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26.82 h EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	13 mg/m² 1 times / day steady-state, intravenous dose: 13 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
25.17 h EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	26 mg/m² 1 times / day steady-state, intravenous dose: 26 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20.2 h EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	52 mg/m² 1 times / day steady-state, intravenous dose: 52 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20.1 h EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	104 mg/m² 1 times / day steady-state, intravenous dose: 104 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26.46 h EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	130 mg/m² 1 times / day steady-state, intravenous dose: 130 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
19.67 h EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	160 mg/m² 1 times / day steady-state, intravenous dose: 160 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.45 h EXPERIMENT https://www.annalsofoncology.org/article/S0923-7534(19)54299-5/pdf	200 mg/m² 1 times / day steady-state, intravenous dose: 200 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16232205/	800 mg/m² 1 times / 3 weeks steady-state, intravenous dose: 800 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	INDISULAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% EXPERIMENT https://journals.lww.com/anti-cancerdrugs/abstract/2003/07000/in_vitro_pharmacokinetic_study_of_the_novel.3.aspx	single, unknown		INDISULAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status:

PubMed

Title	Date	PubMed
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.	2013-10-01	23965175
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.	2010-02	19198760
Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer.	2009-06	19071064
Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.	2009-02	19199010
Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.	2008-10	18637887
Development of small molecule carbonic anhydrase IX inhibitors.	2008-06	18430122
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.	2008-06	17851564
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.	2008-04-22	18414469
Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.	2007-12-01	17826101
Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070).	2007-10	17885589
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.	2007-05-15	17504998
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.	2007-03-15	17363538
A phase I and pharmacokinetic study of indisulam in combination with carboplatin.	2007-02-26	17285128
Targeting tumor-associated carbonic anhydrase IX in cancer therapy.	2006-11	16996620
A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.	2006-10	16946998
Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.	2006-06	16565173
Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.	2005-10	16232205
Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients.	2005-08	16012791
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.	2005-06	15868378
Drugging cell cycle kinases in cancer therapy.	2005-05	15857291
Phase II study of E7070 in patients with metastatic melanoma.	2005-01	15598954
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.	2004-07-15	15269140
Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.	2004-04	14739663
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX.	2004-01-05	14684331
Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.	2004	15517526
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.	2003-11-01	14613999
In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.	2003-07	12853880
Quantitative chemical proteomics for identifying candidate drug targets.	2003-05-01	12720356
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).	2003-05	12736109
New analogues of the anticancer E7070: synthesis and pharmacology.	2003-04	12943191
Indisulam: an anticancer sulfonamide in clinical development.	2003-02	12556221
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).	2002-11	12445024
E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.	2002-11	12439332
Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide.	2002-10-24	12383017
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.	2002-10-01	12351604
An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.	2002-09	12394264
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.	2002-08-15	12177112
Anticancer agent E7070 inhibits amino acid and uracil transport in fission yeast.	2001-12	11723232
E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.	2001-11	11677118
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).	2001-09	11697842
Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells.	2001	11561678

Patents

Sample Use Guides

In Vivo Use Guide

400 mg/ m^2 on days 1 and 8 of a 28-day cycle

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:05:13 GMT 2025` Edited by `admin` on `Mon Mar 31 18:05:13 GMT 2025`
Record UNII	WJ98J3NM90
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INDISULAM

Official Name

English

E-7070

Preferred Name

English

Indisulam [WHO-DD]

Common Name

English

1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)

Systematic Name

English

INDISULAM [MI]

Common Name

English

N-(3-CHLORO-1H-INDOL-7-YL)BENZENE-1,4-DISULFONAMIDE

Systematic Name

English

E7070

Code

English

INDISULAM [USAN]

Common Name

English

indisulam [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29577